Antidopaminergic Medications and Clinical Outcomes in Huntington Disease: Evidence From the PROOF-HD Placebo-Controlled Trial.

What was studied

This post hoc study used the placebo group of the PROOF-HD trial in Huntington disease. It asked if use of antidopaminergic drugs went with clinical outcomes. These drugs include VMAT2 inhibitors and antipsychotics. They are widely used for movement and mental symptoms. 247 people were in the analysis. 135 took these drugs and 112 did not.

What they found

People on these drugs declined faster across several outcome measures. At week 52, the cUHDRS and TFC scores favoured people off the drugs. The gaps ran from week 39 to week 78. Antipsychotic-only use, VMAT2-only use and higher doses were each linked to more decline. Adjusted analyses pointed the same way.

What it means for patients

The authors say use of these drugs was linked to greater worsening. This covered global, daily function, thinking and movement measures. They say drug use, class and dose matter when planning and reading Huntington trials.

Why it is not certain yet

This was a post hoc analysis, not a test planned for this question. People were grouped by drug use, not assigned by chance. The authors say hidden differences in disease severity cannot be fully ruled out. The link does not show that the drugs cause the decline. Only the placebo group was studied.

Source

Antidopaminergic Medications and Clinical Outcomes in Huntington Disease: Evidence From the PROOF-HD Placebo-Controlled Trial.

We restate facts from the source record in our own words. The original wording belongs to its publisher.